Business Wire

EXCELYA

6.7.2020 08:02:10 CEST | Business Wire | Press release

Share
Excelya Welcomes Three European Contract Research Organizations to Become One Stop Provider Throughout Europe

Today, Excelya, a leading contract research organization (CRO) specializing in clinical research, announced that three European CROs joined Excelya Group: Zeincro based in Central-Eastern & Southern Europe, The Clinical Company based in the Netherlands and Belgium and Koehler eClinical based in Germany. Together, they will be known as Excelya Group. This alliance will allow Excelya to offer a one stop provider service model throughout Europe for its clients, whether they need full service, functional service providing or consulting services.

Zeincro is a leading contract research organization primarily operating in Central-Eastern & Southern Europe with particular expertise in clinical operations, safety and medical affairs. The Clinical Company is present in the Belgian and Dutch markets specializing in clinical operations. Koehler eClinical is a German specialty CRO with a focus on biostatistics and data solutions. Thanks to the unification with these three companies, Excelya Group is now a leading European full service CRO providing services in 24 European countries. Excelya Group now employs 800 people in six areas of expertise, with expected combined revenues of €70 million in 2020.

Francois Moisson, CEO at Excelya: “Our newly European scale and reach will allow us to provide a full suite of end-to-end clinical solutions for our clients where they need them. These investments in innovation and delivery capacity position us to rapidly continue our growth in the short and medium term.”

About Excelya Group

Excelya is an independent European contract research organization with over 800 employees, 17 offices and 12 legal entities spread throughout Europe. Excelya offers all cooperation models, from consulting to functional service providing to full-service. It provides these research services across multiple industries, including pharmaceutical, biotech, medical devices, cosmetics and nutrition. As a fully integrated CRO, Excelya undertakes the design and execution of Phase I clinical trials to post-marketing studies, safety, biometrics and market access projects. Excelya is committed to providing preeminent experts who work hand-in-hand with its clients to accelerate end-to-end drug development, leverage data science and reimagine patient care.

For more information, please visit excelya.com .

About Zeincro

Zeincro is a CRO created in 1999 headquartered in the United Kingdom that provides services to more than 20 countries in Central-Eastern & Southern Europe through eight offices. Zeincro provides a full range of services from Phases I to IV with a specialization in clinical operations and safety across most therapeutic areas. With almost 20 years of experience in more than 700 successful clinical studies completed, Zeincro has developed a thorough understanding of the communities and the regions in which it operates. This approach allows ZEINCRO to set new standards for successful clinical trials by delivering bespoke services that maximize patient recruitment and compliance.

For more information, please visit zeincro.com .

About Koehler eClinical GmbH

Koehler eClinical GmbH is a mid-size specialty CRO with more than 25 years of experience in providing value-added services for its customers. With its strong heritage in biostatistics, it covers all study phases as well as biostatistical and regulatory consulting, meta-analyses, data integration and standardizations. As a specialist in data-centric approaches, the company also operates its proprietary software VITESSA as a combined tool for electronic data capture and clinical trial management. Koehler eClinical GmbH provides full-service support for local and global trials with centralized project management and technology-enabled approaches. It covers the full spectrum of clinical projects, from early to late-phase, including NIS, observational and PASS.

For more information, please visit koehler-eclinical.com .

About The Clinical Company

Founded in 2002, The Clinical Company is based in Amstelveen, The Netherlands and Leuven, near Brussels, Belgium. The Clinical Company specializes in delivering clinical services in the Benelux to their (Bio)Pharmaceutical, Medical Device and CRO Clients. The Clinical Company is a full service CRO that provides services from Phases I to IV in all major therapeutic areas and conducts clinical trials in eight countries in Western Europe.

For more information, please visit theclinicalcompany.com .

Project Contributors :

  • Excelya: François Moisson & Frédéric Paqueville (CEO & Co-Founders), Guillaume Steimer
  • Legal counsel:
    • FieldFisher: Philippe Netto, Hélène Lefebvre, Antoine Gabizon (Fr), Mark Walker (UK), Louis Bouchez and Jan Schouten (NL), Florian Streiber (D), Louis-Francois du Castillon (Bel) ;
    • De Pardieu Brocas Maffei: Philippe Rozec
  • Financial Audit: Oderis, Aurélien Vion
  • Financing: Banking pool (SG,LCL, CIC, HSBC), leading agent: Société Générale, Erkan Suer,
  • Zeincro: Dr Gregory Sivolapenko,
  • Koehler eClinical: Dr Manfred Koehler, Dr Antal Hajos, Michael Pfitzenmaier,
  • The Clinical Company: Pim Van de Riet, Chris de Jong, Evert Cuppens, Stijn Valkering, Angélique Kleemans
  • Legal and financial advisors:
    • Zeincro: CMS Cameron McKenna Nabarro Olswang LLP, John Finnemore
    • The Clinical Company: CMS Derks Star Busmann N.V, Pieter van Duijvenvoorde, & Breezeholme Advisory Services, Pim van de Riet
    • Koehler eClinical: Dr. Reinhard Hermes, & VALNES Corporate Finance GmbH, Michael Graser

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BM3EAC Corp. 2026 Semi-Annual Report12.8.2026 17:51:00 CEST | Press release

BM3EAC Corp. (the “Company”), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2026 to 30 June 2026. The semi-annual report can be downloaded from the Company’s website via the following link: https://www.BrigadeM3EAC.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER The Company’s semi-annual report referenced in this announcement may include forward-looking statements, which are based on the Company's current expectations and projections regarding a business combination, the business, the economy and other future conditions of the Company and speak only as of the date hereof. Forward-looking statements may

STL Selects Kinaxis Planning One to Strengthen Supply Chain Planning Across Global Operations12.8.2026 16:10:00 CEST | Press release

Deployment reflects Kinaxis' continued investment in India and expanding access through its growing partner ecosystem Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that STL (NSE: STLTECH), a leading optical and digital solutions company, has selected Kinaxis Planning One to strengthen its supply chain planning capabilities and improve decision-making speed across its global operations. The deployment reflects Kinaxis' continued commitment to the Indian market and represents another milestone in expanding customer access through its growing network of value-added reseller (VAR) partners, and its first customer win through the company's Google Marketplace mid-market initiative. "Manufacturers are under increasing pressure to respond to volatility with faster, more coordinated decisions," said Ray Curbelo, SVP, Global Partner Organization at Kinaxis. "This engagement with STL reflects both the growing demand for modern supply chain planning in Ind

Azalea Vision Appoints Co-Founder Andrés Vasquez Quintero as Chief Executive Officer to Lead Next Phase of Clinical Development12.8.2026 16:00:00 CEST | Press release

Co-founder Andrés Vasquez Quintero assumes the CEO role while continuing as Chief Technology Officer, ensuring leadership continuity. Leadership transition positions Azalea Vision for clinical development of its smart contact lens platform, following selection for the EIC Accelerator. Co-founder Enrique Vega transitions to the Board of Directors, preserving founder continuity. Azalea Vision, a Belgian healthtech company, today announced that co-founder and CTO Andrés Vasquez Quintero will become Chief Executive Officer, effective immediately, while continuing as CTO. The transition marks the company’s next phase, advancing its smart contact lens platform into clinical development, following its selection for the European Innovation Council (EIC) Accelerator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812586109/en/ Andrés Vásquez Quintero, CEO & CTO of Azalea Vision As the inventor of Azalea Vision’s proprietary adapti

Seoul Semiconductor Secures Permanent Injunction in India Following Rulings in Europe and the United States12.8.2026 15:00:00 CEST | Press release

Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890, hereinafter 'Seoul') and its affiliate Seoul Viosys Co., Ltd. (KOSDAQ: 092190), global opto-semiconductor technology companies, have obtained a permanent injunction enjoining infringement of Seoul’s opto-semiconductor patents in India, following similar injunction rulings in Europe and the United States. The Delhi High Court extended the injunction to the managing director as well. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812490873/en/ Patented opto-semiconductor light-output enhancement technology applied in the lawsuits (left) and WICOP technology (right) (Graphic: Seoul Viosys) These rulings are expected to significantly impact the global opto-semiconductor industry, a market worth roughly USD 200 billion that is expanding from automotive lighting and displays into optical communications for AI applications. In India, Seoul Viosys won a final judgment against Ornate

Rimini Street Expands C-Suite Leadership for Growth with Appointment of Two Proven Industry Veterans as Chief Operating Officer and Chief Delivery Officer12.8.2026 15:00:00 CEST | Press release

Rimini Street appoints Keith Costello as EVP and Chief Operating Officer and Alexander Guasch as EVP and Chief Delivery Officer Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced the appointment of Keith Costello as chief operating officer (COO) and Alexander Guasch as chief delivery officer (CDO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812127732/en/ Rimini Street Expands C-Suite Leadership for Growth with Appointment of Two Proven Industry Veterans as Chief Operating Officer and Chief Delivery Officer New COO Brings Proven Experience Scaling Organizations for Growth Keith Costello brings decades of experience building and scaling global enterprise software and services organizations, including leading teams of tens of thousands and managing businesses generating billions of dollars i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye